Drug Trial Radar · NCT04953221
The Effect of YJ001 on Diabetic Peripheral Neuropathic Pain.
Last checked: Nov 19, 2026Latest source record: Jul 7, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
225
Planned (sponsor's estimate)
Start
Jul 1, 2021
Primary completion
Jul 1, 2022
Study completion Jul 1, 2023
Sponsor
- Lead sponsor
- Peking University Third HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 7, 2021
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, a randomized, double-blind, placebo parallel-controlled design was used to evaluate the effectiveness and safety of YJ001 spray applied to local skin in patients with diabetic peripheral neuropathic pain, and to explore the best effective dose.
Conditions
- Diabetic Peripheral Neuropathic Pain
Interventions
YJ001Drug
Skin spray
Primary outcomes
What the sponsor says the trial is designed to measure.
- The change in the average weekly NRS score of pain from baselineTime frame: at the twelfth week after treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Third Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.